Financing led by BVF Partners, L.P. and includes participation from Deep Track Capital and Perceptive Advisors alongside existing investors RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels

本轮融资由BVF Partners, L.P.领投，Deep Track Capital和Perceptive Advisors参与投资，现有投资者RA Capital Management、Insight Partners、英伟达（NVIDIA）、Catalio Capital Management、礼来公司（Eli Lilly and Company）、Cooley以及Gaingels也跟投。

Proceeds will support initiation of a Phase 1 clinical trial in rare, genetic forms of obesity by the end of 2026, as well as continued expansion of GPCR-focused discovery platform

所得资金将支持在2026年底前启动针对罕见遗传性肥胖症的I期临床试验，并持续扩展专注于G蛋白偶联受体（GPCR）的发现平台。

BOSTON

波士顿

,

，

Sept. 3, 2026

2026年9月3日

/PRNewswire/ -- Superluminal Medicines, a biotechnology company integrating AI/ML, protein dynamics and structural biology to rapidly unlock some of the most challenging G protein-coupled receptor (GPCR) targets, today announced the closing of an oversubscribed $60 million Series B financing. Proceeds will support advancing Superluminal's lead program for rare genetic forms of obesity and hypothalamic obesity, expected to begin by the end of 2026; advancing additional pipeline programs; and further expanding the company's portfolio of next-generation small-molecule GPCR-targeted therapies for endocrine and cardiometabolic diseases..

/美通社/ -- Superluminal Medicines 是一家将人工智能/机器学习、蛋白质动力学和结构生物学相结合，以快速攻克最具挑战性的 G 蛋白偶联受体（GPCR）靶点的生物技术公司。该公司今日宣布完成超额认购的 6,000 万美元 B 轮融资。所得资金将用于推进其针对罕见遗传性肥胖和下丘脑肥胖的主要项目（预计于 2026 年底前启动），推进其他管线项目，并进一步扩充其针对内分泌及心脏代谢疾病的下一代小分子 GPCR 靶向疗法产品组合。

BVF Partners, L.P., led the financing, with participation from new investors Deep Track Capital and Perceptive Advisors, along with existing investors RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels.

BVF Partners, L.P. 领投了本轮融资，新投资者 Deep Track Capital 和 Perceptive Advisors 参与投资，现有投资者 RA Capital Management、Insight Partners、NVIDIA、Catalio Capital Management、Eli Lilly and Company、Cooley 以及 Gaingels 也参与了跟投。

'This financing represents an important milestone in Superluminal's evolution as we transition from a discovery platform company to a clinical-stage biotechnology company,' said Cony D'Cruz, Chief Executive Officer of Superluminal Medicines. 'Rare genetic forms of obesity and hypothalamic obesity are devastating diseases with limited treatment options, and we believe our selective, biased MC4R agonist has the potential to make a meaningful difference for these patients.

“此次融资标志着Superluminal在从一家发现平台公司向临床阶段生物技术公司转型过程中的重要里程碑，”Superluminal Medicines首席执行官Cony D'Cruz表示。“罕见遗传性肥胖和下丘脑肥胖是毁灭性疾病，治疗选择有限，我们相信我们的选择性、偏向性MC4R激动剂有望为这些患者带来实质性的改善。”

With the support of this exceptional investor syndicate, we are positioned to advance our first clinical program while continuing to build a pipeline of GPCR-targeted medicines for patients with significant unmet needs in cardiometabolic diseases and obesity.'.

在这一卓越投资者联盟的支持下，我们有望推进首个临床项目，同时继续构建针对G蛋白偶联受体（GPCR）的药物管线，以满足心血管代谢疾病和肥胖症患者尚未被满足的重大医疗需求。

Superluminal's lead clinical program is a selective, biased MC4R agonist being developed for rare genetic forms of obesity and hypothalamic obesity, with a Phase 1 clinical trial expected to begin by the end of 2026. The MC4R pathway is a clinically validated regulator of energy homeostasis and appetite, with established relevance in rare genetic forms of obesity, including Bardet-Biedl syndrome (BBS) and hypothalamic obesity.

Superluminal 的主要临床项目是一款选择性、偏向性的 MC4R 激动剂，正在开发用于治疗罕见遗传性肥胖和下丘脑性肥胖，预计将于 2026 年底前启动 I 期临床试验。MC4R 通路是经临床验证的能量稳态和食欲调节因子，在包括巴德-比德尔综合征（BBS）和下丘脑性肥胖在内的罕见遗传性肥胖中具有明确的相关性。

Because MC4R signaling plays an important role in many metabolic conditions, the program may have future applications in rare diseases such as Prader-Willi syndrome, as well as in the broader population in combination with .

由于MC4R信号传导在许多代谢状况中起着重要作用，该计划未来可能在罕见疾病（如普拉德-威利综合征）以及更广泛的人群中与结合应用。

GLP-1

胰高血糖素样肽-1

therapies. Superluminal's approach is designed to maximize therapeutic activity while minimizing side effects by activating only the signaling pathways responsible for the desired clinical effect. In preclinical studies, the candidate demonstrated high selectivity and a favorable safety profile.

疗法。Superluminal 的方法旨在通过仅激活负责所需临床效应的信号通路，在最大化治疗活性的同时将副作用降至最低。在临床前研究中，该候选药物表现出高选择性和良好的安全性特征。

Superluminal has pioneered the integration of advanced structural biology with proprietary machine learning tools to accelerate the discovery of candidate-ready small molecules. Initially focused on GPCRs—a structurally complex and challenging target class—the platform combines Agentic Cryo-EM capabilities, which enable the generation of hundreds of empirical GPCR structures, with GPCR-focused co-folding models, de novo small-molecule design across diverse 3D pocket conformations, predictive ADME/toxicology models, and novel GPCR biophysics.

Superluminal 率先将先进的结构生物学与专有的机器学习工具相结合，以加速发现候选就绪的小分子。该平台最初专注于 G 蛋白偶联受体（GPCR）——这一类结构复杂且具有挑战性的靶点，其融合了代理式冷冻电镜（Agentic Cryo-EM）能力与针对 GPCR 的共折叠模型、跨多种三维口袋构象的从头小分子设计、预测性 ADME/毒理学模型以及新颖的 GPCR 生物物理学方法。其中，代理式冷冻电镜技术能够生成数百个经验性 GPCR 结构。

Together, these capabilities enable the exploration of functional selectivity and structural complexity at unprecedented scale and form the foundation of Superluminal's next-generation R&D engine. In addition to its wholly owned pipeline, Superluminal continues to advance its strategic collaborations with pharmaceutical partners, including a partnership with Eli Lilly and Company to advance small molecule therapeutics targeting undisclosed GPCRs for cardiometabolic diseases and obesity..

这些能力共同使得在前所未有的规模上探索功能选择性和结构复杂性成为可能，并构成了Superluminal下一代研发引擎的基础。除了其全资拥有的产品管线外，Superluminal还继续推进与制药合作伙伴的战略合作，包括与礼来公司（Eli Lilly and Company）合作，推进针对未公开G蛋白偶联受体（GPCRs）的小分子疗法，用于心血管代谢疾病和肥胖症的治疗。

'We are excited to partner with Superluminal as the company prepares to enter the clinic,' said Harsha Paladugu, Investment Analyst at BVF and member of Superluminal's Board of Directors. 'The lead MC4R program has the potential to address a serious unmet need for patients with rare genetic forms of obesity, and we believe Superluminal's integrated discovery platform has demonstrated the ability to generate differentiated small molecule medicines against historically challenging GPCR targets.'.

“随着Superluminal公司准备进入临床试验阶段，我们很高兴与其建立合作伙伴关系，”BVF投资分析师兼Superluminal董事会成员Harsha Paladugu表示。“其领先的MC4R项目有望满足罕见遗传性肥胖患者尚未被满足的重大医疗需求，我们相信，Superluminal的一体化药物发现平台已展现出针对历史上极具挑战性的GPCR靶点开发差异化小分子药物的能力。”

'The caliber of this financing syndicate speaks to the progress Superluminal has made in establishing a differentiated approach to small molecule drug discovery,' said Nandita Shangari, managing director at RA Capital Management and a member of Superluminal's Board of Directors. 'Bringing together leading healthcare investors alongside existing strategic and technology partners reflects growing confidence in both the company's platform and the team's ability to translate that technology into meaningful clinical programs.

RA Capital Management 的董事总经理、Superluminal 董事会成员南迪塔·尚加里（Nandita Shangari）表示：“该融资银团的阵容彰显了 Superluminal 在建立差异化小分子药物发现方法方面所取得的进展。将领先的医疗健康投资者与现有的战略和技术合作伙伴汇聚一堂，反映出市场对公司平台以及团队将该技术转化为具有临床意义的项目的能力日益增强的信心。”

As Superluminal enters its next phase of growth, the company is well positioned to build a pipeline of innovative medicines for patients in need.'.

随着Superluminal进入其增长的下一个阶段，公司已具备良好优势，能够为有需求的患者构建创新药物研发管线。

About Superluminal Medicines

关于超光速医药

Superluminal Medicines has pioneered the generation and integration of structural biology with proprietary machine learning tools to revolutionize the speed and accuracy of small-molecule drug discovery. The Company's platform aims to create candidate-ready compounds with unprecedented speed using a combination of deep biology, computational and medicinal chemistry, machine learning, and proprietary big data infrastructure.

Superluminal Medicines 率先将结构生物学的生成与整合与其专有的机器学习工具相结合，从而彻底变革小分子药物发现的速度和准确性。该公司的平台旨在通过深度融合生物学、计算化学与药物化学、机器学习以及专有大数据基础设施，以前所未有的速度创制候选化合物就绪的分子。

The Company's proprietary pipeline validates its platform with initial programs focused on high-value GPCR targets, including its wholly owned lead program: a best-in-class, selective, and biased MC4R agonist for the treatment of rare and genetic forms of obesity, expected to enter the clinic by the end of 2026..

公司的专有产品管线通过聚焦于高价值G蛋白偶联受体（GPCR）靶点的初始项目来验证其平台，其中包括其完全自主拥有的领先项目：一种用于治疗和遗传性肥胖症的同类最优、选择性且偏向性的MC4R激动剂，预计将于2026年底进入临床试验阶段。

Media Contact

媒体联系人

Sarah Sutton

莎拉·萨顿

Endurance PR

耐力公关

[email protected]

[email protected]

(518) 932-3680

(518) 932-3680

SOURCE Superluminal Medicines

来源：超光速医药

21

二十一

%

%

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示